Summary of Conference Call Records Industry or Company Involved - **Macro Economy**: Focus on consumption and infrastructure performance - **Overseas Technology**: Google, Trump administration, Apple - **Medical Devices**: Domestic market recovery and international expansion Key Points and Arguments Macro Economy - Consumption and infrastructure show resilience, while real estate, exports, and production face pressure [1][2] - Strong performance in automotive consumption; infrastructure investment is accelerating [1][2] - Real estate market remains under pressure; port operations for imports and exports are slowing down [1][2] - Overall production indicators in sectors like power generation, steel, petrochemicals, and automotive are declining [2] Overseas Technology - Google released Gemini 2.5 Pro, enhancing front-end development and complex programming capabilities [4] - The model allows users to create interactive web applications with simple prompts, significantly lowering entry barriers for developers [4] - Trump administration plans to revoke Biden-era AI chip export restrictions, aiming to simplify regulations and boost innovation [5] - Apple is considering integrating AI search features into its Safari browser, potentially ending its long-standing partnership with Google [6] Medical Devices - The domestic medical device market is expected to face pressure in 2024 due to centralized procurement and bidding rhythms, but international expansion remains positive [7][8] - Domestic market revenue growth for medical devices is projected to be flat or negative in the short term, with a gradual recovery expected as inventory is digested [8] - Key players in the medical device sector include Huatai Medical, Aibo Medical, and others, focusing on domestic replacement and international breakthroughs [7][8] Medical Consumables - Overall performance remains stable, with some high-value consumables experiencing a slowdown due to industry restructuring and price adjustments [9] - The electrophysiology sector is expected to maintain rapid growth due to increased domestic penetration and international market expansion [9] In Vitro Diagnostics (IVD) - The domestic IVD market is under short-term pressure, with revenue growth projected to be negative in the coming quarters [10] - The overseas market is becoming a significant growth point for IVD companies, with expectations for continued expansion [11] Steel Industry - Steel demand has decreased, with inventory levels rising; however, a recovery is anticipated post-holiday [22][24] - The industry is expected to stabilize as real estate demand declines and infrastructure investment continues [24] - Recommendations include leading steel companies like Baosteel and Hualing Steel, which are expected to benefit from industry consolidation and high-quality development [21][24] Other Important but Possibly Overlooked Content - Risks include uncertainties in trade relations, domestic growth policies not meeting expectations, and geopolitical risks affecting the technology sector [2][5][6] - The overall market sentiment is cautious, with a focus on innovation and adaptation in response to regulatory changes and competitive pressures [5][6][9] - The medical device sector is seeing a shift towards domestic production and international market penetration, with significant growth potential in high-end equipment and diagnostics [7][8]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-035 上海澳华内镜股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 第一组 公司于 2025 年 2 月 8 日在上海证券交易所网站（www.sse.com.cn）披露了 《上海澳华内镜股份有限公司股东减持股份计划公告》（公告编号：2025-010）。 君联欣康和高燊拟通过集中竞价、大宗交易方式减持公司股份，合计减持不超过 交易方式减持股份不超过公司股份总数的 1%，自减持计划披露之日起 3 个交易 日后的 3 个月内进行；通过大宗交易方式减持股份不超过公司股份总数的 2%， 自减持计划披露之日起 3 个交易日后的 3 个月内进行。君联欣康和高燊为公司 公司于 2025 年 5 月 12 日收到公司股东君联欣康和高燊出具的告知函。截至 本公告披露日，君联欣康和高燊通过集中竞价方式、大宗交易方式累计减持公司 股份 4,037,469 股，占公司目前总股本的 2.998%。本次减持计划时间区间已届 满，现将具体情况公告如下 ...

上海澳华内镜股份有限公司于2025年5月13日发布股东减持股份结果公告，披露了苏州君联欣康创业投 资合伙企业（有限合伙）（简称"君联欣康"）与高燊有限公司（简称"高燊"）的减持情况。 减持前持股情况 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 点击查看公告原文>> 责任编辑：小浪快报 2025年2月8日，公司在上海证券交易所网站披露《上海澳华内镜股份有限公司股东减持股份计划公 告》。君联欣康和高燊拟通过集中竞价、大宗交易方式合计减持不超过4,037,610股，不超过总股本的 3.00%。其中，集中竞价交易减持不超股份总数的1%，自减持计划披露之日起3个交易日后的3个月内进 行；大宗交易减持不超股份总数的2%，同样自减持计划披露之日起3个交易日 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-035 上海澳华内镜股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 | 股东名称 | 君联欣康、高燊 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股东 | | | | 持股数量 | 6,619,243股 | | | | 持股比例 | 4.92% | | | | 当前持股股份来源 | IPO 前取得：6,619,243股 | | | 上述减持主体存在一致行动人： | | 股东名称 | 持有数量 （股） | 持有比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | | 君联欣康、高燊 | 6,619,243 | 4.92% | 二者实际控制人均 ...

机构专用席位买入额排名：昆船智能(1.03亿元)、若羽臣(4667.06万元)、招商公路(3004.75万元)、锐明 技术(2247.94万元)、科力尔(2173.44万元)、百龙创园(1946.68万元)、中电港(1946万元)、国科军工 (1133.6万元)、陕西华达(1079万元)、康希通信(1035.9万元)、联合水务(1005.95万元)、浙江众成(891万 元)、东微半导(816.6万元)、凌云光(769.3万元)、北元集团(501.76万元)、长盈通(496万元)、灿芯股份 (449.43万元)、星华新材(404.3万元)、征和工业(389.08万元)、西高院(369.6万元)、富吉瑞(352.5万元)、 澳华内镜(323.23万元)、江南奕帆(209.72万元)、和林微纳(202.15万元)、莱宝高科(202.03万元)、华东重 机(201.96万元)、唯万密封(201.35万元)、立讯精密(201.31万元)。 机构专用席位卖出额排名：招商公路(3004.75万元)、龙旗科技(836.6万元)、景嘉微(242.13万元)。 今日(5月12日)A股共62只个股发生大宗交易，总成交12.33亿元 ...

Group 1 - Public fund institutions remained active in research activities, with 146 institutions participating in A-share company research from May 5 to May 11, covering 156 stocks across 24 industries, totaling 1198 research instances [1][2] - The mechanical equipment sector stood out, with LeiSai Intelligent (002979) leading with 54 research instances, attracting nearly 30% of public institutions, while Honghua Digital Technology also received 33 instances [1][2] - The pharmaceutical and biological industry was another focus, with three stocks in the top ten, including Baiji Shenzhou, YiHe JiaYe (301367), and AoHua Endoscopy, receiving 49, 44, and 35 research instances respectively, indicating strong market interest in innovative drugs and medical devices [1][2] Group 2 - The electronic, pharmaceutical, and mechanical equipment sectors were the main areas of focus for public fund research, with electronic industry leading at 201 instances, followed by pharmaceutical at 194, and mechanical equipment at 143 [2] - A significant concentration of research activity was noted, with over 60% of public institutions conducting more than four research activities, and nine leading institutions exceeding 20 research instances [2][3] - Among the top ten active public institutions, Penghua Fund Management conducted 28 research instances, focusing on stocks like Naer Shares (002825), Oulutong (300870), and Honghua Digital Technology, which had notable weekly gains [3]

Core Viewpoint - Public fund institutions remain highly active in conducting research on A-share companies, with a total of 146 institutions participating in 1,198 research instances during the week of May 5 to May 11, 2025, covering 156 stocks across 24 primary industries [1]. Group 1: Top Stocks in Research - The top ten stocks with the highest research frequency include: - LeiHan Intelligent (54 times, +3.41%) - BeiGene (49 times, -6.76%) - YiHe JiaYe (44 times, +10.70%) - DeMingLi (37 times, -3.14%) - XiangXin Technology (36 times, +5.32%) - AoHua Endoscopy (35 times, +4.30%) - WenJian Medical (35 times, -1.47%) - HongHua Digital Science (33 times, +8.77%) - XingYe YinXi (31 times, -1.73%) - ZhouDaSheng (29 times, +0.77%) [2]. Group 2: Industry Focus - The mechanical equipment industry stands out with LeiHan Intelligent leading in research frequency, attracting nearly 30% of public institutions [2]. - The pharmaceutical and biotechnology sector is also a major focus, with BeiGene and YiHe JiaYe ranking second and third in research frequency, respectively [3]. - The electronic, pharmaceutical, and mechanical equipment sectors are the primary areas of interest for public fund research, with a total of 538 research instances, accounting for 44.91% of all public fund research activities [3].

医药生物行业 2024&2025Q1 财报总结：创新与出海驱 动结构性机会 20250511 摘要 • 医药行业估值处于近十年低位，申万医药行业市盈率约为 26 倍，远低于 近十年中枢估值 36 倍和最高估值 73 倍，仅为申万行业平均估值的 76%，具备估值修复空间，但需关注集采政策和创新药入院进度。 • 2024 年医药生物行业营收同比下降 1.4%，归母净利润同比下降 14.4%。但 2025 年 Q1 数据显示，行业营收环比提升 1.78%，归母净利 润环比大幅提升 1,379%，显示出复苏迹象，其中医疗服务和原料药板块 表现突出。 • 化学制剂板块表现最佳，2024 年收入同比增长 2.1%，规模同比增长 35%，归母净利润同比唯一实现正增长，受益于创新政策利好和集采政策 缓和预期。中药板块跌幅最大，但净利率有所恢复，在特定疾病领域仍具 优势。 • 中国制药企业全球化加速，2024 年跨境许可交易总额超 423 亿美元， 2025 年 Q1 中国医药交易金额占全球一半以上，同比增长超 200%，成 为全球医药交易的重要引擎，尤其在肥胖、中枢神经系统等领域表现突出。 Q&A 2025 年医药生物行业的 ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, suggesting a potential for growth in 2025 due to favorable macroeconomic factors and the recovery of public fund allocations to the sector [11]. Core Insights - The pharmaceutical sector is currently undervalued, with public fund allocations at a low point, but is expected to recover, driven by large-scale products and innovations [11]. - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and international pipelines [11]. - In the medical device sector, there is a notable recovery in bidding volumes, particularly for imaging equipment, and a push for home medical devices supported by government subsidies [11]. - The report identifies a significant growth opportunity in the CXO and life sciences services sectors, with expectations of a rebound in domestic financing and a trend towards consolidation [11]. - The traditional Chinese medicine sector is expected to see growth driven by unique essential medicines and state-owned enterprise reforms [11]. Summary by Sections Market Review - The medical device index increased by 0.98%, underperforming the CSI 300 index by 1.03 percentage points, ranking 26th among 30 sectors [8]. - The top ten stocks by growth included JinHao Medical and ChangShan Pharmaceutical, while the bottom ten included ST HuLuWa and YongAn Pharmaceutical [8]. Medical Device Updates - The report notes a significant increase in medical device bidding volumes, with a year-on-year growth of 67.49% in Q1 2025, indicating a strong recovery [20]. - Imaging devices, particularly ultrasound, CT, and DR, are highlighted as the most sought-after categories in procurement [25]. - The report anticipates a surge in procurement activities in county-level medical communities, driven by government support policies [29]. Innovative Drugs - The report emphasizes the growth potential in the innovative drug sector, particularly for companies like BeiGene and Innovent Biologics, which are expected to benefit from their differentiated product pipelines [11]. - The focus on autoimmune diseases is noted as a new growth curve for companies like Nuo Cheng Jian Hua, with significant market potential [37]. Medical Services - The report suggests that the medical service sector will benefit from anti-corruption measures and the expansion of commercial insurance, enhancing the competitiveness of private medical institutions [11]. Blood Products - The blood products sector is expected to grow due to relaxed approval processes for plasma stations and increased demand post-pandemic, with companies like TianTan Biological and BoYa Biological highlighted as key players [11].

Group 1 - The pharmaceutical sector is a key focus for institutional investors, with brokers increasing their investments and research efforts in this area [1] - As of the end of Q1, 14 brokerage firms were among the top ten shareholders of 25 pharmaceutical companies, holding a total of 508 million shares valued at 4.118 billion [1] - In Q1, brokers frequently adjusted their holdings in the pharmaceutical sector, initiating positions in 10 stocks, increasing holdings in 3, and reducing holdings in 11 [1][2] Group 2 - New positions taken by brokers in Q1 included 1.162 billion for Yihe Jiaye and 1.13 billion for Borui Pharmaceutical, with significant holdings also in Jia Ying Pharmaceutical and Chuangguang Medical [2] - Brokers have been actively conducting on-site research to gather firsthand information about the pharmaceutical sector, with over 50 brokers focusing on companies like Aibo Medical and Wanjian Medical [2] - A total of 23 pharmaceutical stocks have been recommended by brokers this month, with notable mentions including Baiji Shenzhou and Heng Rui Pharmaceutical, indicating strong long-term growth prospects [3] Group 3 - The pharmaceutical sector is expected to see a recovery in profitability by 2025, with current PE valuations at historical lows, suggesting potential for excess returns compared to the broader market [3] - Analysts recommend focusing on high-growth, strong recovery, and new expectations for pharmaceutical investments in 2025, particularly in innovative drugs and medical devices [4] - Investment strategies should prioritize companies with significant product advantages and healthy balance sheets, especially those with global sales potential [4]